Landiolol is an ultra-short-acting, highly selective beta1-adrenergic receptor antagonist, or beta-blocker, primarily indicated for the control of heart rate during perioperative and postoperative periods,… Read more























Landiolol is an ultra-short-acting, highly selective beta1-adrenergic receptor antagonist, or beta-blocker, primarily indicated for the control of heart rate during perioperative and postoperative periods, particularly in patients undergoing non-cardiac surgery. It is valued for its ability to manage tachyarrhythmias like postoperative atrial fibrillation while maintaining a stable hemodynamic profile with minimal effects on blood pressure. This category offers a comprehensive selection of pharmaceutical reference standards, including the active pharmaceutical ingredient, along with related impurities, potential degradation products, and stable isotope-labelled compounds. These materials are essential for precise analytical testing, enabling laboratories to perform rigorous impurity profiling, method validation, and stability studies during drug development and quality control. By providing traceable standards, this collection supports the accurate identification and quantification of process-related impurities and metabolites, ensuring compliance with established regulatory requirements for pharmacological safety and efficacy.